We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) RESOLUTE ONYX Meets Primary Study Endpoint
Read MoreHide Full Article
One of the world’s largest medical technology, services and solutions companies, Medtronic plc (MDT - Free Report) recently announced favorable outcome on its Resolute Onyx Drug-Eluting Stent (DES). In a late-breaking trial session at the EuroPCR, the company revealed that Resolute Onyx DES met its primary endpoint of Target Lesion Failure (TLF) at the end of one year on 101 patients with coronary artery disease in extra-small vessels.
Resolute Onyx DES addresses the clinical challenge of treating coronary disease in extremely small arteries with lesions located in difficult-to-reach areas of the heart with greater restenosis rates. The trial results show that at the end of a year, the Resolute Onyx 2.0 mm DES, which is designed for extra-small vessels, derives better clinical outcome than for a pre-specified performance goal with patients experiencing significantly low rates of TLF.
Notably, Resolute Onyx is the first and only DES to feature Core Wire Technology, an advanced form of Continuous Sinusoid Technology (CST) which enables greater deliverability and conformability to vessel walls. Also, the Resolute Onyx DES received approval from the FDA in Apr 2017. It also received CE Mark earlier.
With the device meeting the primary endpoint of TLF at the end of one year, we can expect the company to bolster its position in the growing market of Coronary and Renal Denervation business banking on Resolute Onyx.
The company is currently working on gaining traction in the domestic as well as global market. According to medgadget, the global renal denervation market is expected to witness a CAGR of 11.82% during the 2016–2020 period.
In this regard we note that, for the past three months, Medtronic has been trading above the Zacks categorized Medical - Products industry. The stock has gained 4.5%, higher than the industry’s increase of 4.1%.
Zacks Rank & Key Picks
Medtronic carries a Zacks Rank #3 (Hold). Better-ranked medical stocks include Align Technology, Inc. (ALGN - Free Report) , Hologic, Inc. (HOLX - Free Report) and Baxter International Inc. (BAX - Free Report) . Align Technology sports a Zacks Rank #1 (Strong Buy), while Baxter International and Hologic carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology gained 77.8% in the past one year, better than the S&P 500’s 14.8%. It has a four-quarter average earnings surprise of 19.89%.
Hologic gained 29.2% in the last one year, in comparison to the S&P 500 mark. The company has a stellar four-quarter average earnings surprise of over 5.79%.
Baxter International rose around 33.0% in the last one year, in comparison to the S&P 500. It has a four-quarter average earnings surprise of 17.14%.
Zacks' Hidden Trades While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trade>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Medtronic (MDT) RESOLUTE ONYX Meets Primary Study Endpoint
One of the world’s largest medical technology, services and solutions companies, Medtronic plc (MDT - Free Report) recently announced favorable outcome on its Resolute Onyx Drug-Eluting Stent (DES). In a late-breaking trial session at the EuroPCR, the company revealed that Resolute Onyx DES met its primary endpoint of Target Lesion Failure (TLF) at the end of one year on 101 patients with coronary artery disease in extra-small vessels.
Resolute Onyx DES addresses the clinical challenge of treating coronary disease in extremely small arteries with lesions located in difficult-to-reach areas of the heart with greater restenosis rates. The trial results show that at the end of a year, the Resolute Onyx 2.0 mm DES, which is designed for extra-small vessels, derives better clinical outcome than for a pre-specified performance goal with patients experiencing significantly low rates of TLF.
Notably, Resolute Onyx is the first and only DES to feature Core Wire Technology, an advanced form of Continuous Sinusoid Technology (CST) which enables greater deliverability and conformability to vessel walls. Also, the Resolute Onyx DES received approval from the FDA in Apr 2017. It also received CE Mark earlier.
With the device meeting the primary endpoint of TLF at the end of one year, we can expect the company to bolster its position in the growing market of Coronary and Renal Denervation business banking on Resolute Onyx.
The company is currently working on gaining traction in the domestic as well as global market. According to medgadget, the global renal denervation market is expected to witness a CAGR of 11.82% during the 2016–2020 period.
In this regard we note that, for the past three months, Medtronic has been trading above the Zacks categorized Medical - Products industry. The stock has gained 4.5%, higher than the industry’s increase of 4.1%.
Zacks Rank & Key Picks
Medtronic carries a Zacks Rank #3 (Hold). Better-ranked medical stocks include Align Technology, Inc. (ALGN - Free Report) , Hologic, Inc. (HOLX - Free Report) and Baxter International Inc. (BAX - Free Report) . Align Technology sports a Zacks Rank #1 (Strong Buy), while Baxter International and Hologic carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology gained 77.8% in the past one year, better than the S&P 500’s 14.8%. It has a four-quarter average earnings surprise of 19.89%.
Hologic gained 29.2% in the last one year, in comparison to the S&P 500 mark. The company has a stellar four-quarter average earnings surprise of over 5.79%.
Baxter International rose around 33.0% in the last one year, in comparison to the S&P 500. It has a four-quarter average earnings surprise of 17.14%.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trade>>